On 21 February, ADI wrote to the European Medicines Agency (EMA) to offer its assistance with the assessment of unmet need for those living with dementia and their carers in anticipation of the assessment of new disease modifying therapies. The EMA regulates the availability of medicines across all 27 European Union Member States as well as Iceland, Norway, and Liechtenstein.
In the letter, ADI also stressed the importance of considering safety implications of the new treatments while simultaneously allowing individuals the autonomy to choose and manage their own condition, particularly in the absence of currently approved disease-modifying therapies for Alzheimer’s Disease. ADI also raised concerns about potential disparities in accessing treatments based on wealth or geographic location.
